Advertisement
Advertisement
U.S. markets open in 7 hours 13 minutes
Advertisement
Advertisement
Advertisement
Advertisement

ABVC BioPharma, Inc. (ABVC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.2900-0.0400 (-1.20%)
At close: 04:00PM EST
3.4200 +0.13 (+3.95%)
After hours: 04:02PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close3.3300
Open3.2500
Bid0.0000 x 1800
Ask0.0000 x 900
Day's Range3.2500 - 3.4302
52 Week Range1.9500 - 11.6900
Volume101,627
Avg. Volume2,206,011
Market Cap94.125M
Beta (5Y Monthly)0.31
PE Ratio (TTM)N/A
EPS (TTM)-0.4180
Earnings DateNov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ABVC

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ABVC Biopharma, Inc.
    Daily – Vickers Top Insider Picks for 01/13/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • GlobeNewswire

    ABVC BioPharma Selects Additional Vitargus® Phase II Study Sites

    Thailand Sites Join Australian Sites Confirmed to Participate in the Study Fremont, CA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced two clinical sites in Thailand have been selected to participate in the Phase II clinical study of Vitargus®, the first bio-degradable vitreous substitute intended to facilitate ret

  • GlobeNewswire

    ABVC BioPharma’s Vitreous Substitute Vitargus Presented at 14th APVRS Congress

    Fremont, CA, Dec. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Vitargus®, the world's first bio-degradable vitreous substitute, was presented by Dr. Andrew Chang, MD, Ph.D on December 11, 2021 at the 14th Asia-Pacific Vitreo-Retina Society (“APVRS”) Congress. APVRS, one of the most prestigious ophthalmology confe

  • GlobeNewswire

    ABVC BioPharma Medical Device Vitargus Receives Taiwan National Innovation Award

    Fremont, CA, Dec. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Vitargus®, its vitreous substitute intended to facilitate retina re-attachment surgery, received the 2021 “National Innovation and Renewal of Diligence” award from the Institute for Biotechnology and Medicine Industry (IBMI) of Taiwan. The award was p

Advertisement
Advertisement